Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

Orazio Caffo; Giovanni Lo Re; Teodoro Sava; Sebastiano Buti; Cosimo Sacco; Umberto Basso; Fable Zustovich; Michele Lodde; Alessandra Perin; Gaetano Facchini; Antonello Veccia; Francesca Maines; Carmen Barile; Lucia Fratino; Angela Gernone; Rocco De Vivo; Giovanni L. Pappagallo; Enzo Galligioni

doi:10.2217/fon.14.284

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

Orazio Caffo, Giovanni Lo Re, Teodoro Sava, Sebastiano Buti, Cosimo Sacco, Umberto Basso, Fable Zustovich, Michele Lodde, Alessandra Perin, Gaetano Facchini, Antonello Veccia, Francesca Maines, Carmen Barile, Lucia Fratino, Angela Gernone, Rocco De Vivo, Giovanni L. Pappagallo, Enzo Galligioni

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL. Patients & methods: All patients received DOC 70 mg/m every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients' QL.

Original language	English
Pages (from-to)	965-973
Number of pages	9
Journal	Future Oncology
Volume	11
Issue number	6
DOIs	https://doi.org/10.2217/fon.14.284
Publication status	Published - Mar 1 2015

Keywords

castration-resistant prostate cancer
docetaxel
intermittent chemotherapy
quality of life
randomized trial

ASJC Scopus subject areas

Oncology
Cancer Research
Medicine(all)

Access to Document

10.2217/fon.14.284

Cite this

Caffo, O., Lo Re, G., Sava, T., Buti, S., Sacco, C., Basso, U., Zustovich, F., Lodde, M., Perin, A., Facchini, G., Veccia, A., Maines, F., Barile, C., Fratino, L., Gernone, A., De Vivo, R., Pappagallo, G. L., & Galligioni, E. (2015). Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. Future Oncology, 11(6), 965-973. https://doi.org/10.2217/fon.14.284

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. / Caffo, Orazio; Lo Re, Giovanni; Sava, Teodoro; Buti, Sebastiano; Sacco, Cosimo; Basso, Umberto; Zustovich, Fable; Lodde, Michele; Perin, Alessandra; Facchini, Gaetano; Veccia, Antonello; Maines, Francesca; Barile, Carmen; Fratino, Lucia; Gernone, Angela; De Vivo, Rocco; Pappagallo, Giovanni L.; Galligioni, Enzo.

In: Future Oncology, Vol. 11, No. 6, 01.03.2015, p. 965-973.

Research output: Contribution to journal › Article › peer-review

Caffo, O, Lo Re, G, Sava, T, Buti, S, Sacco, C, Basso, U, Zustovich, F, Lodde, M, Perin, A, Facchini, G, Veccia, A, Maines, F, Barile, C, Fratino, L, Gernone, A, De Vivo, R, Pappagallo, GL & Galligioni, E 2015, 'Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients', Future Oncology, vol. 11, no. 6, pp. 965-973. https://doi.org/10.2217/fon.14.284

Caffo, Orazio ; Lo Re, Giovanni ; Sava, Teodoro ; Buti, Sebastiano ; Sacco, Cosimo ; Basso, Umberto ; Zustovich, Fable ; Lodde, Michele ; Perin, Alessandra ; Facchini, Gaetano ; Veccia, Antonello ; Maines, Francesca ; Barile, Carmen ; Fratino, Lucia ; Gernone, Angela ; De Vivo, Rocco ; Pappagallo, Giovanni L. ; Galligioni, Enzo. / Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. In: Future Oncology. 2015 ; Vol. 11, No. 6. pp. 965-973.

@article{da5f4e7cb2424861a0342c7c148bf901,

title = "Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients",

abstract = "Aims: The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL. Patients & methods: All patients received DOC 70 mg/m every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients' QL.",

keywords = "castration-resistant prostate cancer, docetaxel, intermittent chemotherapy, quality of life, randomized trial",

author = "Orazio Caffo and {Lo Re}, Giovanni and Teodoro Sava and Sebastiano Buti and Cosimo Sacco and Umberto Basso and Fable Zustovich and Michele Lodde and Alessandra Perin and Gaetano Facchini and Antonello Veccia and Francesca Maines and Carmen Barile and Lucia Fratino and Angela Gernone and {De Vivo}, Rocco and Pappagallo, {Giovanni L.} and Enzo Galligioni",

year = "2015",

month = mar,

day = "1",

doi = "10.2217/fon.14.284",

language = "English",

volume = "11",

pages = "965--973",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

AU - Caffo, Orazio

AU - Lo Re, Giovanni

AU - Sava, Teodoro

AU - Buti, Sebastiano

AU - Sacco, Cosimo

AU - Basso, Umberto

AU - Zustovich, Fable

AU - Lodde, Michele

AU - Perin, Alessandra

AU - Facchini, Gaetano

AU - Veccia, Antonello

AU - Maines, Francesca

AU - Barile, Carmen

AU - Fratino, Lucia

AU - Gernone, Angela

AU - De Vivo, Rocco

AU - Pappagallo, Giovanni L.

AU - Galligioni, Enzo

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Aims: The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL. Patients & methods: All patients received DOC 70 mg/m every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients' QL.

AB - Aims: The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL. Patients & methods: All patients received DOC 70 mg/m every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients' QL.

KW - castration-resistant prostate cancer

KW - docetaxel

KW - intermittent chemotherapy

KW - quality of life

KW - randomized trial

UR - http://www.scopus.com/inward/record.url?scp=84924972911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924972911&partnerID=8YFLogxK

U2 - 10.2217/fon.14.284

DO - 10.2217/fon.14.284

M3 - Article

C2 - 25760977

AN - SCOPUS:84924972911

VL - 11

SP - 965

EP - 973

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 6

ER -

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this